GlassScriptPhysician profile
Steven P Stowers
NPI 1891883609
$15,587.60
in general payments reported to CMS, 2019-2025
50 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $1,989 · 2021: $2,513 · 2022: $2,408 · 2023: $2,201 · 2024: $2,163 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,596.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,592.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,293.68 | 2019-2025 | |
| Lilly USA, LLC | $1,166.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,164.54 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Glaxosmithkline, LLC. | $924.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $641.46 | 2019-2024 | Trintellix |
| Abbvie INC. | $526.05 | 2021-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $493.30 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $483.06 | 2020-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $382.29 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $374.43 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $353.28 | 2020-2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $261.38 | 2019-2023 | |
| Amarin Pharma, INC. | $220.04 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.